Detail akcie AnaptysBio Rg online

Business Summary: AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, AnaptysBio Inc revenues increased from $48.2M to $126.4M. Net loss decreased 49% to $62.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects antibody product segment loss decrease of 82% to $19M. Basic Earnings per Share excluding Extraordinary Items increased from -$4.48 to -$2.08.